Search results for: 'drug ad data'

Drug-resistant bacteria, or superbugs, pose a serious threat to human health. Developing new antibacterial drugs requires a great deal of time, effort, expenditure, and scientific research, making it a less-attractive segment for investment by pharmaceutical companies. This research service focuses on the global antibacterial drugs (antibiotics) ma...

Cities are evolving toward a more sustainable and efficient model. A focus area is reducing carbon emissions by adopting renewable energy sources like solar and wind power and promoting electric vehicles. In addition, there is a shift toward pedestrian-friendly urban design, with wider sidewalks, bike lanes, and increased green spaces. Cities want ...

The global pharmaceutical research and development (R&D) pipeline accounts for more than 21,000 molecules, as of April 2023, indicating a 5.8% hike over 2022, with more than 6,100 molecules in active development. In general, however, the pharma/biopharma industry has stagnated with respect to R&D activity. Overall R&D expenditure totals about $276....

The evolution in autonomy and increase in the adoption of driver assistance systems have generated a need to sense and perceive the surrounding environment of a vehicle entirely and accurately. The fusion of forward-looking sensor data has given OEMs and Tier-I suppliers opportunities to offer multiple ADAS applications at low costs, while providin...

01 Mar 2024  |  North America  |  Market Research

Global Orphan Drug Growth Opportunities

Reduced Exclusivity and Increased Competition will Drive Demand for More Efficient R&D and Digital Solutions

Infographics

×

In this study, Frost & Sullivan s Transformational Health team provides critical insights into the global orphan drug (OD) industry and highlights growth opportunities, revenue, regulatory changes, and technology trends influencing growth. Approximately 5% of rare diseases (RDs) have received US FDA approval for a drug, while up to 15% of RDs have ...

The treatment of rare diseases requires the use of specialized drugs. Patient populations for rare diseases are most often quite small, consequently the products treating them earn the designation orphan drugs. These drugs must undergo the research, development, and clinical trials that all drugs do, yet the investment into the development is great...

Server-side ad insertion has normally been about tackling the problems of ad blocking and device fragmentation. But the industry is now seeing platform shifts that change the sweet spot of ad stitching towards live and catch-up TV. Client-side ad SDKs have grown in sophistication, the platforms they run have become more capable and the transition t...

With the healthcare industry moving toward patient convenience and comfort, pharmaceutical and medical device companies are continuously researching for the most effective, side effect free, convenient route of drug delivery. Transdermal drug delivery is a painless method of delivering drug formulation. Transdermal route of drug administration has ...

13 Jun 2023  |  North America  |  Market Research

US Healthcare Data Analytics, 2023

Competitive Intensity is Driving Innovation Among Healthcare Data Analytics Vendors

Infographics

×

This report offers a comprehensive analysis of the US healthcare data analytics market. The analysis focuses on solutions for payers and providers (including physician practices and hospitals). Solutions for the life sciences segment, pharmaceutical companies, and the public sector have been excluded. This study categorizes healthcare data analytic...